Stephen R. Hanson

Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL.

TargetRx, Inc. provides pharmaceutical and biotech enterprises with insight into the drivers of prescribing. The firm offers various solutions, which include forecasting, positioning, and promotional decisions for new drug launches; optimizing marketing messages and materials for campaign development; and measurement and optimization of execution for sales and marketing execution. TargetRx was founded by Michael J. Luby and Sangam Pant in 1999 and is headquartered in Horsham, PA.

Valley Forge Pharmaceuticals, Inc. develops ophthalmic pharmaceuticals. It is an early stage ophthalmic pharmaceutical company focused on preventing the development of myopia in children and utilizing proprietary pharmaceutical drugs to control abnormal ocular development. The company is headquartered in Irvine, CA.

Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.

Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA.

Part of River Acquisition Corp., IVAC Corp. is a company that manufactures electronic medical equipment. The company is based in San Diego, CA. IVAC was acquired by River Acquisition Corp. from Eli Lilly & Co. on November 29, 1994.

Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ.

The Wistar Institute provides biomedical research services. It researches on diseases such as cancer, cardiovascular, autoimmune disorders and infectious diseases and develops vaccine. The company was founded in 1892 and is headquartered in Philadelphia, PA

BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million.

Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The company is based in St. Peter Port, UK.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993.

NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.